Home  »  Company  »  Alembic Pharmaceutic  »  Quotes  »  Notes to Account
Enter the first few characters of Company and click 'Go'

Notes to Accounts of Alembic Pharmaceuticals Ltd.

Mar 31, 2013

I Segment Reporting

Primary Segment

The Company has identified "Pharmaceuticals" as the only primary reportable segment.

In view of the inter-woven/inter-mixed nature of business and manufacturing facility other secondary segmental information is not ascertainable.

II Disclosures in respect of Related Parties pursuant to Accounting standard - AS 18 - issued by the Institute of Chartered Accountants Of India pursuant to Companies (Accounting Standards) Rules 2006 are as follows

List of Related Parties with whom the Company has entered into transactions during the yean

a) Controlling Companies: There is no controlling Company

b) Subsidiary and Fellow Subsidiary:

1 Alembic Global Holding SA (Subsidiary of Alembic Pharmaceuticals Limited)

2 Alembic Pharmaceuticals Australia Pty Ltd (Subsidiary of Alembic Global Holding SA.)

3 Alembic Pharmaceuticals Europe Ltd (Subsidiary of Alembic Global Holding SA.)

4 Alnova Pharmaceuticals SA (Subsidiary of Alembic Global Holding SA.)

5 Alembic Pharmaceuticals Inc. (Subsidiary of Alembic Global Holding SA.)

c) Associate Companies:

1 Alembic Ltd.

2 Whitefield Chemtech Pvt. Ltd.

3 Nirayu Pvt. Ltd.

4 Quick Flight Ltd.

5 Shreno Ltd.

6 Paushak Ltd.

7 Sierra Investments Ltd.

8 Viramya Packlight Ltd

9 Incozen Therapeutics Pvt. Ltd.

10 Rhizen Pharmaceuticals SA

d) Key Management personnel

1 Shri C .R. Amin Chairman and Managing Director

2 Shri R. K Baheti Director, President - Finance & Company Secretary

3 Shri Pranav Amin Director, President-International Business

4 Shri Shaunak Amin President - Formulations

e) Relatives of Key Management Personnel :

1 Smt. Malika Amin

2 Shri Udit Amin

3 Ms.Yera Amin

4 Ms. Jyoti Patel

5 Ms. Ninochaka Kothari

6 Ms. Shreya Mukherjee

III The previous year''s figures have been regrouped / rearranged wherever necessary to make it comparable with the current year


Mar 31, 2012

(a) The rights, preferences and restrictions including restrictions on the distribution of dividends and the repayment of capital;

The company is having only one class of shares i.e Equity carrying a nominal value of Rs 2/- per share Every holder of the equity share of the Company is entitled to one vote per share held

In the event of liquidation of the Company, the equity shareholders will be entitled to receive remaining assets of the Company after the distribution / repayment of all creditors. The distribution to the equity shareholders will be in proportion of the number of shares held by each shareholder

The Company declares and pays dividend on the equity shares in Indian Rupees. Dividend proposed by the Board of Directors is subject to approval of the shareholders at the ensuing Annual General Meeting

During the year ended 31st March, 2012 an amount of Rs 1.40 of dividend per equity share was proposed for the equity shareholders ( PY Rs 1/- per equity share)

i. Segment Reporting

Primary Segment

The Company has identified "Pharmaceuticals" as the only primary reportable segment.

In view of the inter-woven/inter-mixed nature of business and manufacturing facility, other secondary segmental information is not ascertainable.

ii During the year ended 31st March, 2012 the revised schedule VI notified under the Companies Act, I956 has become applicable to the Company for perperation and presentation of its financial statement. The adoption of revised schedule VI does not impact recongination and measurement principles followed for preparation of financial statements. However, it has significant impact on presentation and disclosures made in the financial statements. The company has also reclassified the previous year's figures in accordance with the requirements appliable in the current year. In view of this reclassification certain figures of current year are not strictly comparable with those of the previous year.

 
Subscribe now to get personal finance updates in your inbox!